Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated neuropathy. It affects peripheral nerves and roots. CIDP has no biomarkers. It may be monophasic ...

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and ...

(RTTNews) - argenx SE (ARGX) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved VYVDURA for adults with chronic inflammatory demyelinating polyneuropathy. VYVDURA is ...

Dutch immunology specialist argenx announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) approved Vyvdura ...

Argenx Se ( (ARGX) ) has provided an update. Argenx SE announced that Japan’s Ministry of Health, Labour and Welfare has ...

Vyvdura receives Japanese regulatory approval for adults with chronic inflammatory demyelinating polyneuropathy: Rotterdam, the Netherlands Monday, December 30, 2024, 1 ...

Argenx (ARGX) announced that Japan’s Ministry of Health, Labour and Welfare, or MHLW, approved Vyvdura for adults with chronic inflammatory demyelinating polyneuropathy. Vyvdura is approved for CIDP ...

(RTTNews) - argenx SE (ARGX) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved VYVDURA for adults with chronic inflammatory demyelinating polyneuropathy. VYVDURA is ...

for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVDURA was approved for CIDP as a once weekly 30-to-90 second subcutaneous injection, which can be self-administered at ...